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Abstract
Background A wide range of diseases, normal variations in physiology
and development of different species are caused by alterations in gene reg-
ulation. The study of gene expression is thus crucial for understanding
both normal physiology and disease mechanisms. High-throughput mea-
surement technologies allow the profiling of tens of thousands of genes
simultaneously. However, the high volume of data thus generated poses
methodological challenges in inferring biological consequences from gene ex-
pression changes. Traditional gene wise analysis of high dimensional data is
overwhelming, prone to noise and unintuitive. The analysis of sets of genes
(gene set analysis, GSA), solves the problem by boosting statistical power
and biological interpretability. Despite more than a decade of research on
gene set analysis, there are still serious limitations in the existing methods.
Aims of the study The objectives of this study were: (1) development
of an efficient p-value estimation method for GSA; (2) development of an
advanced permutation method for GSA of multi-group gene expression data
with fewer replicates; and (3) implementation of the developed methods for
the identification of novel smoking induced epigenetic signatures at biolog-
ical pathway level.
Materials and methods The first study involved the assessment of four
different statistical null models for modeling the distribution of gene set
scores calculated with the Gene Set Z-score (GSZ) function from permuted
gene expression data. A new GSA method - modified GSZ (mGSZ) - based
on GSZ and the most optimal distribution model was developed. mGSZ was
evaluated by comparing its results with seven other popular GSA methods
using four different publicly available gene expression datasets. The second
study involved the evaluation of six different permutation schemes for GSA
of multi-group (more than two groups) datasets based on the identification
of reference gene sets generated using a novel data splitting approach. A
new GSA method based on a modification of mGSZ (mGSZm) was de-
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veloped by implementing the best permutation method for the analysis of
multi-group data with fewer than six replicates per group. mGSZm was
evaluated by contrasting its performance with seven other state-of-the-art
GSA methods suitable for multi-group data. The evaluation was based
on three different publicly available multi-group datasets. The third study
involved an implementation of mGSZ for GSA of genome-wide DNA methy-
lation data from the Cardiovascular Risk in Young Finns study (YFS) co-
hort with gene sets downloaded from the Molecular Signature Database
(MSigDB). Methylation measurements were done on a subset of 192 in-
dividuals from whole-blood samples from the 2011 follow-up study using
Illumina Infinium HumanMethylation450 BeadChips.
Results Overall, efficient and robust GSA methods were developed (stud-
ies I-II) and implemented (study III). In study I, the results demonstrated
a clear advantage of asymptotic p-value estimation over empirical meth-
ods. mGSZ, a GSA method based on asymptotic p-values, requires fewer
permutations which speeds up the analysis process. mGSZ outperformed
state-of-the-art methods based on three different evaluations with three dif-
ferent datasets. In study II, results from a novel evaluation approach with
two different datasets suggested that the proposed advanced permutation
method outperformed the naive permutation method in GSA of multi-group
data with fewer than six replicates. Evaluation of mGSZm, a GSA method
equipped with the advanced permutation method and asymptotic p-value
estimation method, showed that the method is robust and, despite only
using fewer than six replicates, is able to consistently identify a high pro-
portion of relevant gene sets in three different multi-group datasets. In
study III, GSA of YFS methylation data using mGSZ identified a total
of 13 significant (false discovery rate ≤ 0.05) smoking related pathways.
The results included a novel finding that the highly regenerating olfactory
sensing system responds to tobacco smoke and toxin exposure through epi-
genetic mechanisms. Besides the novel finding, the study also confirmed
previous findings of smoking induced alteration in methylation in biolog-
ical pathways involved in lung tissue repair and maintenance, chronic in-
flammation, lung cancer, platelet function, thrombosis and nervous system
development.
Conclusions In this thesis: i) a novel approach of efficient p-value esti-
mation for permutation based GSA was introduced, ii) an advanced permu-
tation method for GSA of multi-group data with fewer than six replicates
was developed, and iii) a novel smoking related epigenetic signature was
iii
identified using the developed methods.
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Chapter 1
Introduction
1.1 Transcriptomics and epigenetics
1.1.1 Central Dogma of Molecular Biology
The Central Dogma of Molecular Biology describes the process of gene
expression. Gene expression is the process by which the genetic code in
the DNA (deoxyribonucleic acid) is used for the synthesis of functional
gene products like proteins and RNAs. DNA is the hereditary material in
humans and most other organisms. Most DNA is located in cell nucleus
densely packed into thread-like structures called chromosomes. The part of
DNA that is present in mitochondria is called mitochondrial DNA. DNA
is made up of four chemical bases: adenine (A), guanine (G), cytosine (C),
and thymine (T). The sequence of these chemical bases, about 3 billion
in total in humans, form the genetic code of DNA [22]. Genes, the basic
physical and functional unit of life, are segments of the DNA string that
are transcribed into RNA and then translated into a functional protein.
In humans, there are estimated to be 20000 to 25000 protein-coding genes
with size varying from a few hundred to more than 2 million bases [105].
Genes carry the instruction needed to code a protein.
1.1.2 Transcriptomics
In gene expression, the first step is transcription that involves the forma-
tion of protein-coding or non-coding regulatory RNA molecules from a gene
with the help of an enzyme called RNA polymerase. The collection of RNA
molecules transcribed in a cell and a tissue is called the transcriptome. The
second step is translation when messenger RNA (mRNA) is decoded to pro-
1
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duce a specific amino acid chain with the help of ribosomes. The amino
acid chain folds into an active protein and performs its functions in the
cell. Gene expression, thus, acts as a proxy for translation and translation
events that represent a snapshot of a biological state.
Assuming that a normal cell has a standard gene expression profile, a shift
in the profile is assumed to be indicative of altered protein level and con-
sequently an altered biological state. Thus, gene expression measurement
and analysis is important for studying the molecular mechanism of an al-
tered biological state like disease, the identification of diagnostic or prog-
nostic markers, the classification of diseases, monitoring the response to
a therapy and understanding the molecular mechanism of biological pro-
cesses. However, it is important to note that several studies have reported
poor agreement between mRNA levels and the corresponding protein levels
[76, 71] which could be due to several reasons such as complicated post-
transcriptional mechanisms, different in vivo half-lives of proteins, error
and/or noise in protein and mRNA measurements and different protein
turnover rates.
Advances in molecular biology technologies allow genome-wide profiling of
many genes simultaneously. Analysis of such high-throughput gene expres-
sion data is used to identify genome-wide differences in the levels of gene
transcription between different experimental groups such as healthy con-
trols and people with certain disease. DNA microarrays, invented in the
1990s, are microscope slides with thousands of tiny spots at defined posi-
tions [72]. The spots contain DNA molecules that act as probes to detect
gene expression. Probes are specific DNA molecule designed to target a
gene or other DNA element by DNA hybridization with a complementary
DNA strand. The probe-target gene hybridization generates fluorescence,
the intensity of which is detected and quantified to estimate the relative
expression level of target genes. The underlying rationale is that gene ex-
pression levels are directly proportional to the level of probe-gene hybridiza-
tion. Gene expression analysis starts with experimental design that starts
with sample collection. During sample collection, care should be taken in
minimizing sources of variation other than those under investigation. For
example, in a case-control study, matching or pairing of the samples must
be done appropriately to avoid the effects of a confounding variable. The
decision of the number of technical and/or biological replicates is another
aspect of experimental design for reliable statistical inference. Generally,
three replicates are a minimum requirement for a reliable statistical test.
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Once the sample collection is done, mRNA samples (for example, from
whole blood) are collected, labelled and applied to the microarray. Proper
quality assurance should be taken during collection, isolation, storage and
preservation of RNA/DNA samples. A sufficient amount of high quality or
intact RNA is crucial in any molecular biology experiments. Analysis of
the generated data must account for technical artifacts that can arise from
sources such as different date, lab, technician, microarray chip or failed
hybridization.
Despite their popularity, microarrays have several limitations. Measure-
ment accuracy for genes that are mildly expressed is limited by background
hybridization. An experiment is limited to the genes which have probes
available in the microarray. A more recent high-throughput sequencing
technology called as RNA sequencing (RNA-Seq) addresses the limitations
by directly sequencing the transcripts [86]. RNA-seq has rapidly replaced
microarrays for whole-genome transcriptome profiling because of its ability
to detect novel transcripts, allele-specific expression and splice junctions
[112]. Recently, there has been growing interest in transcriptomics of sin-
gle cells through single-cell RNA sequencing technologies. This holds great
potential in revealing biological insights of health and disease at cellular
level as compared to traditional bulk population based methods [115].
1.1.3 Epigenetics
Epigenetics is the study of heritable changes in gene expression that is not
due to any changes of the DNA sequence itself. Virtually all cells in an
organism contain the same DNA. Yet, not all genes are expressed simulta-
neously in all cell types. Epigenetic changes determine whether or not a
particular gene is expressed in a particular cell type, thereby influencing the
production of cell specific proteins. For example, genes that code for protein
needed for bone growth are turned on in bone cells but turned off in muscle
cells. The epigenome constitutes all the chemical compounds that regulate
the activity (expression) of all the genes within the genome. The chemical
compounds are not part of the DNA sequence but are attached to DNA and
can be inherited through generations. The epigenome can be affected by
environmental factors like diet, smoking and pollutants. Three major epige-
netic changes are DNA methylation, histone modification and non-coding
RNAs (Figure 1.1) [94]. Histones are proteins responsible for condens-
ing the DNA of eukaryotic cell nuclei and organizing it into units called
nucleosomes. Post-translational modification to histone proteins such as
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Figure 1.1: A schematic diagram showing different epigenetic mechanisms;
histone modification, methylation and posttranscriptional regulation by Mi-
croRNAs (miRNAs).
methylation, phosphorylation, acetylation, ubiquitylation and sumoylation
changes chromatin structure and consequently alters gene expression. Non-
coding RNAs (ncRNAs) are RNA molecules that are transcribed from DNA
but not translated into proteins [48]. These molecules can be categorized
into two major groups; the short ncRNAs (<30 nucleotides) and the long
ncRNAs (>200 nucleotides). Short ncRNAs include microRNA (miRNA),
short interfering RNA (siRNA) and piwi-interacting RNA (piRNA). Mi-
croRNAs, which are small RNA molecules of 17 to 24 nucleotides, are one
of the most widely studied non-coding RNAs. MicroRNA silences gene ex-
pression by binding to the 3′UTR of its target-gene’s mRNA.
DNA methylation is one of the major epigenetic factors influencing gene ex-
pression through the addition of methyl groups to the DNA molecule. DNA
bases (cytosine and adenine) can be methylated. Adenine methylation has
been observed in bacterial, plant and recently also in mammalian DNA
[106]. Cytosine methylation which is common in bacteria and eukaryotes,
1.2 Gene Set Analysis 5
is the most studied type of methylation. Cytosine methylation involves the
transfer of a methyl group from S-adenyl methionine to the fifth carbon of
cytosine residue catalyzed by a family of DNA methyltransferases to form
5-methylcytosine. The process plays a critical role in the regulation of gene
expression and consequently in mammalian development and diseases [44].
Genome-wide profiling of human DNA methylation used in this study was
based on whole blood sample and Infinium HumanMethylation450K Bead-
Chip (450K methylation array). The high-throughput technology is based
on the following principle. Bisulphite treatment of DNA converts cyto-
sine residues to uracil. However, methylated cytosine (5-methylcytosine)
residues are unaffected by this treatment. This property of cytosine residues
provides the “gold standard” approach to assess the DNA methylation sta-
tus at single-nucleotide resolution. CpG sites are regions on DNA where
cytosine and guanine appear consecutively in the 5′to 3′direction. The “p”
stands for the phosphodiester bond that joins the two nucleotides. CNG
sites, on the other hand, are sites with consecutive cytosine and guanine
nucleotides with any nucleotide in between. The array includes a total of
485,764 cytosine sites out of which 482,421 are CpG (99.3%) and 3,343 are
CNG (0.7 %) sites. It is based on two different chemistries; Infinium I and
Infinium II. Infinium I contains two probes per methylation site, one for
methylated and another for unmethylated query site. The 3′terminus of
the probes is designed such that it matches either the methylated cytosine
or the thymine base (resulting from bisulphite treatment or present in the
genome). Infinium II, on the other hand, has only one probe per methy-
lation site. The 3′terminus of the Infinium II probe is designed such that
it complements the base directly upstream of the query site. Identification
of methylation is based on single base extension that results in addition
of a labeled G or A base, complementary to either the “methylated” C or
“unmethylated” T.
1.2 Gene Set Analysis
1.2.1 Motivation
In recent years, the advent of high-throughput molecular profiling tech-
niques and their rapid evolution thereafter have revolutionized the way
bioscience research is done. For example, there has been a major shift in
the approach to studying disease, from the traditional individual molecule-
wise study to system-level studies. With this benefit, there also came a
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challenge to be able to interpret the huge list of molecules generated from
the analyses of high-throughput data, which is often noisy.
The fundamental goal of genome-wide omics experiments is the detection
of biological processes or pathways that behave consistently differently be-
tween groups of samples under different conditions. The traditional ap-
proach for analyzing such data is the identification of individual differen-
tially expressed molecules such as genes. A typical approach is to perform
statistical tests such as analysis of variance (ANOVA) and select a list
of genes based on an arbitrary p-value threshold. The selected genes are
studied individually for their biological relevance. Gene-wise analysis of
genome-wide data for that purpose has the following problems: i) no single
gene may be differentially expressed based on the chosen threshold, ii) an
overwhelming number of genes may be differentially expressed without a
unifying biological theme (unintuitive), iii) differentially expressed genes
with multiple functions are hard to interpret.
One approach to address the problems is to analyze the list of molecules
group-wise, where the grouping is based on some prior knowledge. The
idea was introduced by [117] who analyzed microarray data by first group-
ing open reading frames into clusters based on the similarity of their ex-
pression patterns, followed by enrichment analysis of the clusters against
pre-defined functional categories. The approach was originally developed of
analyzing a list of genes and hence called as GSA. The approach solves the
problems as: i) it increases the statistical power as smaller but consistent
changes in all the genes in a set is likely to stand out clearly as opposed
to individual genes (larger signal to noise ratio), ii) gene level noise signals
cancel out when analyzed as a group, iii) it provides intuitive results if
the genes in a set are related with respect to a common biological theme.
The approach involves the calculation of gene set scores analogous to gene
scores such as t-scores or fold change. The approach has several names such
as “gene set analysis”, “functional annotation”, “pathway analysis”, “gene
set enrichment analysis” and “gene list enrichment analysis”. From here
onwards, we refer the approach collectively as “Gene Set Analysis (GSA)”.
Even though the earlier gene set analysis methods were developed particu-
larly for transcriptomics and differential expression analysis, the approach
is applicable to all types of genome-wide omics data ([100]).
1.2 Gene Set Analysis 7
Figure 1.2: A schematic diagram showing different types of gene set anal-
ysis.
1.2.2 Gene sets
Gene sets are genes grouped together based on shared biological features
like biological pathways, transcription factors or chromosomal location.
The type of gene sets to be used in an analysis depends on the research ques-
tion. Several databases or resources such as Gene Ontology (GO) [5], [24],
Kyoto Encyclopedia of Genes and Genomes (KEGG) [56], Reactome Path-
way Database [28] and Molecular Signatures Database (MSigDB) [114], [68]
provide different types of gene set collections.
1.2.3 Types
Many different GSA methods have been developed over the last decade.
The methods can be categorized into different types described in this sec-
tion (Figure 1.2.3).
GSA methods can broadly be categorized into three generations. Meth-
ods belonging to the first generation are the earliest GSA methods com-
monly called over-representation analysis (ORA) or enrichment analysis.
Over-representation based methods determine the overlap between a test
gene list and a curated database like gene ontology, looking for overlaps
that are bigger than that expected by chance. The most common method
to obtain the list of genes is to get a list of differentially expressed genes
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based on an arbitrary threshold such as p-value and/or fold change. The
idea was first implemented by [117]. ORA methods are based on statistical
tests like the hypergeometric test, Fisher’s exact and chi-squared (i.e the
problem can be formulated in point of view of different statistical tests).
There are several freely available tools for ORA [11], [50]. Some of the ORA
methods take into account the differential expression as a score calculated
as a product of p-value and fold change. These methods are quick and easy
to implement but have several limitations, including:
(i) Applicable only when differentially expressed genes are found
(ii) Results change with arbitrary p-value thresholds
(iii) Disregards gene-gene correlation
(iv) Massive reduction in sensitivity
Second generationGSAmethods are called functional class scoring (FCS)
methods. FCS methods are threshold free (i.e., they do not require p-value
thresholds) and thus utilize all the genes in a gene set (whether or not
differentially expressed) to calculate a gene set score. In contrast to ORA,
threshold based selection of gene list is not required, which guarantees a
unique result for each dataset. Furthermore, this approach allows the iden-
tification of significant gene sets among weakly but coherently regulated
genes. These methods can be based on signal summary scores [90, 118] or
ranked lists [84, 12, 17]. Signal summary based methods use the whole gene
list and calculate a gene set score as a function of the gene set members’ gene
scores (e.g., t-scores or fold change scores). An obvious drawback of the sig-
nal summary approach is that the method assumes homogeneous behavior
of the members of a gene set. This assumption is violated in cases where
a gene set contains both up and down-regulated genes or where genes have
been misclassified as members of the gene set. Ranked list based methods
go through the whole ordered gene list and analyze over-representation of
the gene set at every possible threshold and the threshold with the highest
score is selected. A drawback with this approach is that it ignores scores
associated with genes (example, t-scores or fold change). The assumption
of a constant step between consecutive genes is violated in real datasets as
there are usually drastic changes in gene expression at the tails of ordered
gene lists. [114] proposed a GSA method combining signal summary and
rank list. The combination mitigates the above mentioned limitations of
signal summary and ranked list based methods. The method calculates
gene set statistics based on over– or under-representation and gene level
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scores over the ordered gene list to find the strongest signal.
Third generation GSA methods, called the pathway topology-based ap-
proach, incorporate biological network structure into the analysis to ac-
count for gene-gene correlation [83]. These methods take gene-gene cor-
relation into account by weighting genes based on their relationship with
other genes in a gene set. For example, a gene that is correlated to only
one other gene in a gene set is given less weight as compared to a gene that
is correlated to more than one gene in the gene set. In addition to gene
sets data, these methods require gene-gene interaction data or knowledge
of pathway structure.
GSA categorization based on Null hypothesis
Based on the null hypothesis tested, GSA methods can be either com-
petitive or self-contained. The null hypothesis of self-contained methods
states that none of the genes in a gene set are associated with the pheno-
type. These methods are useful when a researcher is interested in testing
whether one or a few gene sets of interest is/are associated with the phe-
notype. Methods proposed by [42], [77], [60], [30], and [126] are examples
of self-contained gene set analysis methods. Competitive gene set analy-
sis methods test whether the genes in a gene set are more associated to
the phenotype as compared to other genes (genes not in the analyzed gene
set). These methods are used to rank collection of gene sets based on the
strength of their association with the phenotype. GSEA [114], GSA [34]
and CAMERA [127] are examples of competitive gene set analysis.
This thesis is focused on signal and ranked list based functional class scoring
GSA methods that test competitive null hypothesis. For simplicity, we will
refer this class of methods as gene set analysis (GSA) methods in the rest
of the thesis.
1.2.4 Gene set scoring functions
GSA involves two parts; 1) calculation of a gene set score as a function of
gene level statistics (for example t-scores or fold change scores) of member
genes of the analyzed gene set, and 2) estimation of the statistical signifi-
cance of the gene set score. The gene set score quantifies the magnitude by
which genes in a gene set are overrepresented in either end of the ranked
gene list. This Section describes popular gene set scoring functions used in
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this thesis.
Kolmogorov-Smirnov statistic (KS-statistics)
The Kolmogorov-Smirnov test is a non-parametric test, i.e., the test does
not require data to follow any known statistical distribution distribution.
The purpose is to either test for differences in the shape of two sample distri-
butions or to compare the distribution of a sample to an expected statistical
distribution. The test compares the overall shape of distributions instead of
central tendency, dispersion or other parameters. Thus, the null hypothesis
for two sample test is that two samples are drawn from populations with
the same distribution. The KS-statistics is simply the maximum absolute
difference between the two cumulative distribution functions. The gene set
score in GSEA [114] is based on KS-statistics which is calculated as follows;
1. Perform differential gene expression analysis and rank the genes based
on their differential gene expression scores, for example t-scores.
2. Compute cumulative sum over the ranked genes as follows:
(a) Increase sum if gene is in the analyzed gene set, decrease it
otherwise.
(b) The magnitude of the increment depends on the strength of as-
sociation of the gene with phenotype.
3. The maximum deviation from zero is the gene set score.
4. Normalization of Enrichment Score for multiple testing correction
step.
The maxmean statistic
[34] proposed maxmean statistics as a gene set score and showed that this
statistic is more powerful than the modified KolmogorovSmirnov statistic
used in GSEA. For a given gene set, the mean of the positive or nega-
tive part of gene scores (for example, differential expression test scores) is
calculated. The maxmean statistics is the value that is larger in absolute
value. Note that the mean of the positive or negative part of gene scores
is calculated by dividing the sum by total number of genes in the gene set
instead of total number of positive or negative gene scores. This makes the
gene set score sensitive to large gene scores in either or both directions.
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Wilcoxon rank-sum statistic
The Wilcoxon Rank-Sum (WRS) test is a rank based non-parametric test
for comparing two groups of observations without the assumption of any
distribution. The gene set score is simply the sum of ranks of member
genes of the analyzed gene set in the whole gene list. [122] proposed a two-
sided WRS test to compare the ranks of the genes belonging to a gene set
with the ranks of the remainder of the genes. WRS is also implemented in
SAFE (Significance Analysis of Function and Expression) [10] as the gene
set scoring function.
Random-set enrichment score (Allez)
The random-set enrichment score is based on the comparison of the sum of
differential expression scores of gene set members to the expected average
of a random set of genes of the same size and also to the expected variance
of a random set of genes of the same size [88]. For the analyzed gene set,
the score is first calculated as a raw average of gene scores in the set. The
score is a random variable because the gene set is a random set of genes
among the gene pool in the data. The enrichment score is based on the
comparison of the analyzed gene set score with a hypothetical gene set
from the same dataset. As the analyzed gene set can be considered as a
random gene set with m genes drawn uniformly from the pool of genes in
the dataset without replacement, it is equivalent to gene label permutation.
The gene set score is obtained by standardization of the raw score (average
of member gene scores of the set) by substracting the global mean of gene
scores and dividing the difference with global variance that depends on the
size m of the gene set. The method has been implemented in an R package
Allez. For simplicity, we refer this method as Allez in the rest of the text.
Sum (SUM) and sum of squares (SS) based GSA scores
Gene set scoring functions based on the sum and sum of squares were also
used as reference GSA methods in this thesis. The sum statistic is the
simple sum of the differential gene expression test scores of the member
genes of the analyzed gene set with background subtraction. The sum of
squares statistic is simply the squared version of SUM.
Gene Set Z-score (GSZ)
GSZ combines the signal summary and ranked list based approach by cal-
culating a statistic that is based on under– or over-representation and by
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analyzing the whole gene list for the strongest signal. The approach is sim-
ilar to that of GSEA except that GSZ involves the derivation of the mean
and standard deviation for normalizing the gene set score as a Z-score.
Input The first step in gene set analysis with GSZ involves the calculation
of gene scores. Gene scores can be: i) differences in the gene expression pro-
files between two compared groups such as treatment and control groups,
or ii) the association of the gene expression profile with a continuous pheno-
type such as waist size measurement of a cohort participants. The genes are
then sorted based on the gene scores and used as input for gene set analysis.
Derivation Given a ranked gene list, a subset is taken for gene set score
calculation by placing a threshold. The process of selecting subsets of the
ranked list and calculating the score is done repetitively by placing the
threshold consecutively after each gene. Thus, the analysis involves the
calculation of scores for subsets ranging in size from one gene to all the
genes in the ranked list. The following list of notations will be used in the
derivation;
• M : Total number of genes in a subset
• Xi, i = 1, ...,M : Gene score for ith gene.
• N : Number of genes that belong to analyzed gene set (member genes)
• L: Total number of genes in the whole gene list
• K: Number of member genes in the whole gene list
• S: Sum of expression levels of N genes
For a given subset from a ranked gene list, the gene set score is simply a
difference between the sums of member and non-member genes,
Diff =
∑
Xmember −
∑
Xnon−member, (1.1)
which is calculated separately for each subset and analogously for the lower
part of the ranked gene list. The calculated difference is unstable due to its
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sensitivity to differences in size of analyzed gene sets, ranked gene subsets
and variances of the gene scores in different subsets. The instability can
be solved by normalizing the difference (equation 1.1) with its estimates
of expected value and variance under the null hypothesis that the member
and non-member genes are distributed randomly across the ranked gene list,
Z =
Diff − E(Diff)√
D2(Diff)
(1.2)
where E(Diff) is the expected value of the difference given by,
2E(X)E(N)−ME(X),
and D2(Diff) is the variance of the difference given by,
4(D
2(X)
M−1 (E(N)(M − E(N))−D2(N)) + E(X)2D2(N)),
where E(N) is the mean and D2(N) is the variance of the hypergeometric
distribution of the number of genes, N , in the analyzed gene set for the
analyzed subset. D2(X) and E(X) are the variance and the mean of the
differential expression test scores for the subset.
Derivation of expected value The expected values for the sum of mem-
ber or non-member gene scores in the equation 1.1 can be defined using
conditional probabilities:
E(S|M,L,K) = E(
∑
Xn)
=
∑
P (N = i)E(S|N = i), (1.3)
which is the sum of expected value of S conditional on the number of mem-
ber genes weighted with the probability of having that number of member
genes in the analyzed subset. Equation 1.3 is equivalent to:
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E(S|M,L,K) =
∑
P (N = i)iE(X), (1.4)
as the expected value of the sum conditional on the number of member
genes is equivalent to the expected value of gene scores of member genes
of the analyzed subset multiplied by the number of member genes. The
expected value of equation 1.1 can be defined as:
E(Diff |M,L,K) =
∑
i
P (N = i)iE(X)−
∑
i
P (N = i)(M − i)E(X)
= E(X)(
∑
i
P (N = i)i−
∑
i
P (N = i)(M − i))
= E(X)(2
∑
i
P (N = i)i−M)
= E(X)(2E(N)−M)
= 2E(X)E(N)−ME(X),
(1.5)
which leads to a simple function of: i) the expected value of hypergeometry
distribution E(N), ii) the expected value of gene scores in the analyzed
subset E(X), and iii) the number of genes M in the analyzed subset. E(X)
is calculated by taking empirical mean from the whole subset.
Derivation of variance The variance for sum of member or non-member
gene scores in the equation 1.1 can be defined as:
D2(S|M,L,K) = E(S2)− E(S)2
=
∑
i
P (N = i)E(S2|N)− E(S)2, (1.6)
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For simplicity, lets consider the case where N is fixed. Then, the expec-
tation E(S2|N) can be expressed as a sum of the variance and squared
expectation,
E(S2|N) = D2(S|N) + E(S|N)2
= D2(Xi)
N(M −N)
M − 1 + E(X)
2N2, (1.7)
The first term of the equation 1.7 represents the variance of the sum of N
values selected from a pool of X1, X2, ..XM values with variance D
2(X)
which is estimated empirically from the subset. The derivation of D2(S|N)
is taken from supplementary text S1 of the original GSZ article [119]. Sub-
stituting equation 1.9 to equation 1.6 gives the following:
D2(S|M,L,K) =
∑
i
P (N = i)E(S2|N)− E(S)2
=
∑
i
P (N = i)(D2(Xi)
i(M −N)
M − 1 + E(X)
2i2)
− E(X)2E(N)2
= D2(X)
∑
i
P (N = i)
(Mi− i2)
M − 1 + E(X
2)
∑
i
P (N = i)i2
− E(X)2E(N)2
=
MD2(X)
M − 1
∑
i
P (N = i)i− D
2(X)
M − 1
∑
i
P (N = i)i2
+ E(X)2(E(N2)− E(N)2)
=
MD2(X)E(N)
M − 1 −
D2(X)(D2(N) + E(N)2)
M − 1 + E(X)
2D2(N)
=
D2(X)
M − 1 (E(N)(M − E(N))−D
2(N)) + E(X)2D2(N)
(1.8)
16 1 Introduction
The final derivation of equation 1.8 involves equations of the mean and
variance of the hypergeometric distribution (E(N), D2(N)), the gene score
of the subset of data (E(X), D2(X)) and the size of the subset (M). Equa-
tion 1.8 represents the variance of one of the summations of the equation
1.1. The complete variance in equation 1.1 can be derived by multiplying
equation 1.8 with the squared constant 22. The final Gene Set Z-score is
thus obtained as:
Z =
Diff − E(Diff)√
D2(Diff)
=
Diff − E(X)(2E(N)−M)
2
√
D2(S)
=
∑
Xmember −
∑
Xnon−member − E(X)(2E(N)−M)
2
√
D2(S)
=
∑
Xmember −ME(X) +
∑
Xmember − E(X)(2E(N)−M)
2
√
D2(S)
=
2
∑
Xmember −ME(X)− E(X)(2E(N)−M)
2
√
D2(S)
=
2
∑
Xmember −ME(X)− 2E(X)E(N) +ME(X)
2
√
D2(S)
=
2
∑
Xmember − 2E(X)E(N)
2
√
D2(S)
=
∑
Xmember − E(X)E(N)√
D2(S)
(1.9)
1.2.5 P-value estimation
The P-value is the probability of seeing the observed or more extreme re-
sults when the null hypothesis is true. P-values and statistical significance
have been recently criticized [2]. However, p-values were used in this thesis
work as a way to estimate the most informative gene sets for biological
analysis. Based on the method used to estimate p-value, GSA can be ei-
ther permutation based or parametric. Parametric p-values are calculated
from an assumed underlying distribution of gene set scores. For example,
Irizarry et al., [51] and Kim and Volsky [58] proposed fully parametric
gene set analysis methods based on a normal approximation of the gene set
scores. Strong statistical assumptions of the parametric approach are not
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always met. Permutation based p-value can be calculated by permuting ei-
ther genes or samples. Sample-wise permutation preserves the correlation
structure among genes in a gene set and is thus more preferable. Ideally,
p-value estimation is done by comparing the original test statistics with
test statistics obtained from all possible permutations of the sample labels.
However, it is computationally not feasible to consider all possible permuta-
tions to generate the null distribution. For example, in case of a moderately
big gene expression dataset with two groups and 10 biological replicates per
group, The total number of permutations while excluding mirror image is
1
2
(20)!
10!(20−10)! = 92378. Generally, in practice a subset of permutations are
chosen for p-value estimation, the most common in GSA being 1000-2000
permutations (Figure 1.3). The problem with this approach is that the min-
imum obtainable p-value varies with the chosen number of permutations.
Gene set scores with real p-values less that 1/(number of permutations)
will be assigned zero thus limiting researcher’s ability to rank the gene sets
based on their significance.
1.2.6 Permutation
A permutation test is a non-parametric statistical procedure to determine
the statistical significance of a test statistic based on rearrangements of the
class labels of a dataset. The test essentially constructs a null distribution
(sampling distribution for the test statistic under the null hypothesis) in-
stead of assuming one as is the case with parametric methods. Permutation
tests are useful in situations where there are insufficient data or evidence
to support a particular statistical model for the analyzed measurements.
The null hypothesis, in the context of GSA, is tested by first calculating
the gene set score, the test statistic with the original gene expression data.
Next, the null distribution is computed with a permutation test. A large
number of samples (gene set scores) under the null hypothesis is needed
to estimate the sampling distribution. A large number of datasets can be
generated by random rearrangement of the sample labels (referred to as
permutations hereafter). A gene set score is calculated from each of the
rearranged or permuted data. Permuting of sample labels will have no
effect on the outcome when null hypothesis is true. The P-value for the
gene set score is estimated by ranking the original gene set score among
the permuted gene set scores.
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Figure 1.3: Diagrammatic representation of sample permutation based
competitive gene set analysis workflow.
Chapter 2
Aims of the present study
The aims of this study were: (a) to develop novel sample permutation
based competitive gene set analysis methods addressing the limitations in
the most popular current methods, and (b) to implement the developed
methods to identify active smoking induced epigenetic signatures in bio-
logical processes. The specific aims were covered in the following three
publications:
I. Develop efficient p-value estimation method for permutation based
gene set analysis (Publication I).
II. Develop advanced permutation method for sample permutation based
gene set analysis of multi-group data with fewer than six replicates
(Publication II)
III. Identify smoking related epigenetic signatures by gene set analysis of
genome-wide methylation data (Publication III).
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Chapter 3
Materials and Methods
3.1 Asymptotic p-value estimation
P-value estimation by fitting several candidate statistical distribution mod-
els (Section 3.1.1) on a null distribution of gene set scores generated from
permuted gene expression data was evaluated. The most optimal distribu-
tion model based on the evaluations was applied to GSZ and the updated
method is called modified GSZ (mGSZ). mGSZ was evaluated by compar-
ing its performance with seven other popular gene set analysis methods
(Section 3.1.3) on multiple datasets (Section 3.1.4).
3.1.1 Extreme Value Distribution
Extreme value distributions are used to model extreme or rare events, for
example, extreme flood, temperature or snowfall. Extreme value theory
that deals with such events states that the maximum or minimum of the
collection of random observations from the same distribution can be mod-
eled with the extreme value distribution [61]. The class of extreme value
distribution involves three types of distributions - type I (Gumbell), II
(Frechet) and III (Weibull).
The GSZ score of a gene set represents the absolute maximum score among
the scores calculated over all the thresholds (score set) in the given ranked
gene list (Section 1.2.4). Thus, GSZ scores of a gene set in N permuted
data are the largest values from N score sets. Assuming that these N score
sets are from the same distribution, the GSZ scores from N permuted data
can be described by extreme value distributions. We used type I, referred
to as EVD here onwards, and the generalized EVD that combines the three
types, referred to as GEVD here onwards.
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Figure 3.1: Probability density functions for type I, II and II extreme value
distrubutions.
Extreme value type 1 distribution (EVD)
The EVD is defined by the following probability density function,
f(x) =
1
β
e
− (x−μ)
β e−e
− (x−μ)
β
(3.1)
and the cumulative distribution function is given by,
F (x) = e−e
−(x−μ)/β
(3.2)
where, μ is the location parameter and β>0 is the scale parameter. Stan-
dard extreme value type I distribution has μ = 0 and β = 1.
General extreme value distribution (GEVD)
The general extreme value distribution (GEVD) is a flexible three parame-
ter model that combines the extreme value type I, II and III distributions.
The probability density function of the GEVD is given by,
f(x) =
{
1
β e(−(1 + az)−
1
a )(1 + az)−1−1/a a = 0 1β e(−z − e(−z))
a = 0
(3.3)
.
The cumulative distribution function is,
3.1 Asymptotic p-value estimation 23
F (x) =
{
e(−(1 + az)−1/a) a = 0
e(−e(−z)) a = 0 (3.4)
.
where, z = (x - μ)/β and a, β, μ are shape, scale and location parameters
respectively. The scale must be positive, the shape and location can take
on any real value. The sign of shape parameter tell which of the extreme
value type I, II and III distributions fits the data (μ = 0: type I, μ >0:
type II, μ <0: type III) (Figure 3.1).
3.1.2 P-value calculation with series expansion
EVD and GEVD based p-values were calculated from cumulative distribu-
tion function of the fitted extreme value distributions on null distribution
of GSZ scores as,
P-valueEV D = 1− CDFEV D(X), (3.5)
where CDFEV D is the cumulative distribution function of EVD and X is
the gene set score. The calculation of extremely small p-values is difficult
as the CDFEV D(X) approaches 1 due to limited number precision in com-
puting systems. This problem was solved by deriving series expansions on
the logarithm of the p-value for EVD and GEVD. This series expansion in
combination with asymptotic p-value estimation allows the estimation of
extremely small p-values with a moderate number of permutations.
3.1.3 Reference GSA methods used in evaluation
The evaluation of the asymptotic p-value estimation method was based on
comparison of the results generated with mGSZ and seven other popular
GSA methods implemented by ourselves (Table 3.1). mGSZ was also com-
pared with GSA methods with available implementations as R packages
(Table 3.1).
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Table 3.1: GSA methods used as reference for evaluation of asymptotic
p-value estimation method and mGSZ.
Compared GSA
methods
Descriptions
GSA
Maxmean statistics based method with empirical p-value estimation method
implemented as R package [34].
Allez
Random-set enrichment score based method implemented as R package
[88].
mGSA
Our improved version of maxmean statistics based method included in mGSZ
R package.
mAllez
Our improved version of random-set enrichment score based method included in
mGSZ R package.
WRS Wilcoxon rank-sum statistics based method with empirical p-value estimation
method.
SS Sum of squares based method with empirical p-value estimation method.
SUM Sum based method with empirical p-value estimation method.
KS Kolmogorov-Smirnov statistics based method with empirical p-value estimation
method.
wKS
Weighted Kolmogorov-Smirnov statistics based method with empirical p-value
estimation method [114]
.
CAMERA
Correlation adjusted mean rank gene set test method implemented in R package
[127]
ROAST Rotation based gene set analysis method implemented in R package [126].
3.1.4 Datasets used in evaluation
Datasets used in evaluation of asymptotic p-value estimation methods and
mGSZ were downloaded from the GSEA web site (http://software.broadinstitute.
org/gsea/datasets.jsp). The datasets have been used as benchmark
datasets in the evaluation of popular gene set analysis methods such as
GSEA [114] and GSA [34].
P53 cancer data P53 is a gene in human that encodes for tumor protein
p53 which is a tumor suppressor protein that prevents development of can-
cer cells. The P53 cancer dataset consists of genome-wide transcriptional
profiles with 33 samples with a mutated p53 gene and 17 samples with the
wild type p53 gene [114].
Gender data The gender dataset consists of transcriptional profiles from
15 males and 17 females lymphoblastoid cell lines [114].
Leukemia data The leukemia dataset consists of gene expression profiles
of cells from 24 acute lymphoid leukemia patients and 24 acute myeloid
leukemia patients [3].
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3.1.5 Evaluation of asymptotic p-value estimation method
In order to evaluate the accuracy of the asymptotic p-values, we generated a
“reference of truth” by calculating GSZ scores and their empirical p-values
with 100000 sample permutations of the original data. Empirical p-values
were calculated as the number of null GSZ scores greater than or equal to
the test GSZ score divided by the total number of permutations. This is
based on the assumption that empirical p-values calculated with 100000
sample permutations are closer to the true p-values. The asymptotic p-
values were evaluated by calculation their Pearson correlation (cor) and
mean squared error (mse) with log transformed empirical p-values. While
correlation indicates the magnitude and direction of a linear relationship,
mean squared error indicates the difference between asymptotic p-values
(test p-values) and empirical p-values (the reference of truth). In addi-
tion to the whole list, the analysis was repeated on the signal rich region
of p-values by calculating cor and mse also for the subset of p-values <
0.10. This emphasizes the biologically interesting regions of the gene list.
An optimality criterion was defined for the tested statistical distributions.
Distributions with mse<0.10 and cor>0.97 in both the whole list and the
signal rich regions were considered to be optimal distributions for asymp-
totic p-value estimation. The evaluation of asymptotic p-values was done
with two different microarray gene expression datasets: (a) P53 cancer data
(b) Gender data.
We did the same experiment with two other gene set scoring functions:
GSA [34] and Allez [88]. The best statistical distribution models for p-
value estimation of GSA and Allez gene set scores turned out to be EVD
and NORM (gaussian), respectively. We present modified versions of GSA
and Allez referred to as mGSA and mAllez respectively. mGSA includes
two modifications: (1) substitution of max-mean statistics with GSZ, (2)
substitution of empirical p-value estimation with asymptotic p-value esti-
mation. mAllez includes one modification, that is, the addition of sample
permutation on top of implicit gene permutation.
3.1.6 Evaluation of mGSZ: new evaluation principles for
GSA methods
Literature lacked robust and unbiased evaluation principles for GSA meth-
ods. This work developed several approaches for multi-perspective evalua-
tion of a GSA method.
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Identification of relevant gene sets
Competitive gene set analysis methods aim to identify gene sets that are
more associated with phenotype or “relevant” compared to a random set
of genes of same size from the data. Thus, the most straightforward eval-
uation approach would be to score the methods based on the number of
relevant gene sets identified. However, we lack knowledge of the relevant
gene sets (or the truth). In this study, relevant gene sets were defined based
on literature mining and transcription factor (TF) activity.
Relevant gene sets based on literature mining The top n (for ex-
ample, n = 20 in the case of gender data and n = 50 in the case of p53
cancer data) most significant gene sets reported by each of the compared
methods were pooled. Each of the pooled gene sets was then analyzed sep-
arately for their relevance to a condition or exposure by intensive literature
mining, for example, gene sets relevant to p53 activity in P53 cancer gene
expression data. Methods were compared for the number of relevant gene
sets in top (for example, 20 in the case of gender data and 50 in the case of
p53 cancer data) gene sets reported. The results were presented as a plot
of the cumulative count of the number of relevant gene sets on the y-axis
against the top n gene sets on the x-axis.
Relevant gene sets based on TF activity Gene expression data from
transcription factor (TF) deletion and overexpression experiments is an-
other useful tool for evaluating gene set analysis methods because the ex-
perimental perturbations of TFs provide the standard-of-truth for the eval-
uation of methods. The gene sets in such setting can be defined as targets
genes of TFs. Unlike biological processes, TFs can be directly controlled
and adjusted (such as overexpression or deletion) to have an expected ef-
fect on the expression levels of target genes. The evaluation is based on
the ability of the compared methods to identify TFs based on changes in
expression levels of their targets genes. This idea was implemented by [87]
for the comparison of 14 different gene set analysis methods. The exper-
imentally perturbed TFs were considered positive gene sets and an ideal
gene set analysis method should identify the perturbed TFs. As the dataset
had no biological replicates, the gene sets were ranked based on empirical
p-values calculated with 100000 gene permutations. For each experiment,
the area under curve (AUC) was calculated and the compared methods
were ranked based on the mean and standard deviation of the AUC.
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False positive test
The idea in the false positive test is to investigate if a method has a tendency
to create false-positive results when gene sets are in fact not associated
with the studied condition or exposure. The compared methods were run
with the original gene expression data but with null gene sets generated by
randomly choosing the member genes while keeping the gene set size intact.
The performance of the compared methods was evaluated by examining the
distribution of p-values reported from the leukemia dataset.
3.2 Advanced permutation method
Six different permutation methods (Section 3.2.1) were evaluated for the
analysis of multi-group gene expression data with less than six replicates
per group. All the permutation methods were implemented with GSZ.
Thus, there were six different GSA methods based on the six different per-
mutation methods. The permutation methods were evaluated based on
the performance of the GSA method implementing them. As the only
difference between the six methods is the type of permutation, the differ-
ence in their performance is due to the permutation method. THe evalu-
ation of permutation methods was based on the identification of reference
gene sets generated by a data split method (Section ??) on two different
datasets (Section 3.2.3). The most optimal permutation method identified
after evaluation was implemented in mGSZ. The mGSZ method updated
with advanced permutation method for multi-group data is referred to as
mGSZm. mGSZm was evaluated by comparing its performance to seven
other GSA methods (Table 3.2) in the analysis of three different multi-group
gene expression datasets (Section 3.2.3).
3.2.1 Advanced permutation methods
Advanced permutation methods, in the context of this work, are meant to
be used for pairwise comparisons of chosen exposures/groups. The main
idea underlying the methods is to employ all the groups (including also
the groups other than those being compared) for the estimation of the
null distribution. The assumptions underlying the methods are that: 1)
there is same inherent structure, including gene-gene correlations, across
all groups, 2) the differential gene expression score represents gene regula-
tion and co-regulation of member genes, 3) a gene set represents regulation
of the associated biological process. The null hypothesis that the outcome
is not related to group status must hold true with the null distribution.
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In the context of GSA, if for example, one is interested in comparing a
group with a particular disease with a healthy group, a test statistic under
the null hypothesis should have nothing to do with the healthy vs. disease
categorization. In this study, we generated a null distribution for a pair-
wise comparison by permuting the compared groups as well as the other
groups. In doing so, there could be a situation where highly correlated
samples end up in the compared groups giving test statistics as extreme
as the one obtained with original data. We call this phenomena leakage of
biological signal which leads to false negative results (Figure 3.2). The goal
of this study was to develop a permutation method for generating a null
distribution of gene set scores from a pair-wise comparison in multi-group
gene expression data while controlling for biological leakage.
We evaluated six different permutation methods, referred to as Perm1-6
hereafter. The methods differ from each other in the way they model the
background signal of the data. Perm1 is a naive permutation method lim-
ited only to the groups being compared. Perm2-6 are candidate approaches
that aim to prevent signal leakage by ensuring that the permuted groups do
not contain many samples from a single original group or highly correlated
groups. Identification of the most optimal permutation method for such
dataset is not trivial. The degree of randomness in picking samples from
groups in a dataset for permuted data plays a crucial role in the leakage
of biological signal. Complete randomness can result in highly correlated
samples ending up in the same group in the permuted data, thus producing
false negative results. On the other hand, too constrained a method can
generate false positive results. In order to find an optimal balance, perm2-6
were designed such that sampling is the least constrained in perm2 and most
constrained in perm6. For example, perm2 picks samples randomly from
all sample groups and can group highly correlated samples. The following
notations will be used in describing the permutation methods:
n: Number of replicates in a group. For simplicity, we let n(= 5) be
constant for all groups.
m: Total number of groups in multi-group gene expression data (= 6
in our example).
y: Total number of samples in all the groups.
z: Total number of samples in the groups being analyzed.
B and D: The groups that we are interested to compare.
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B∗ and D∗: Permutations of the analyzed groups B and D.
X: Number of permutations.
N |Permx|: Total number of permutations from permutation method
x.
Perm1
This is the naive permutation method used in gene set analysis of two-group
gene expression data. In case of multi-group data, perm1 based gene set
analysis considers only the compared groups and the rest is ignored. Only
the samples from the groups being compared are permuted (Figure 3.3).
The number of unique permutations using perm1 is given by:
N |Perm1|= 1
2
z!
n! (z − n)! (3.6)
The factor 1/2 is included to exclude permutations that are mirror images
of one another and give identical results, such as (1,1,0,0) and (0,0,1,1). In
a multi-group gene expression dataset with m = 6 and n = 5, the total
number of obtainable permutations is 126. Thus, perm1 cannot generate
sufficient permutations needed to construct a reliable hull distribution.
Perm2
Perm2 involves rearrangement of all the samples in the data irrespective of
the pair of groups being analyzed. For example, in a data with six groups,
if we are interested in analyzing groups B and D, the permuted groups B∗
and D∗ will include random samples from the compared as well as any of
the other groups (Figure 3.4). This might allow situations where permuted
groups may not contain any sample from the compared groups or may
contain many or all samples from their respective original groups. Thus,
there is a risk of generating an unreliable null distribution, for example, by
incorporating biological signal. The total number of unique permutations
by perm2 is given by,
N |Perm2|= 1
2
y!
n!n! (y − 2n)! (3.7)
that gives 3.8e + 9 unique permutations from the example dataset with
m = 6 and n = 5.
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Figure 3.2: Examples of biological leakage during generation of null data.
Case and control groups under the bad permutations example contain ma-
jority of replicates from similar or highly correlated sample groups, which
can potentially introduce biological signal into null data. In contrast, un-
der the good permutations example, case and control groups contain well
mixed samples from all different groups in dataset.
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Figure 3.3: Schematic diagram representing Perm1.
Figure 3.4: Schematic diagram representing Perm2.
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Perm3
In multi-group data with m>n, permutations are generated in two steps:
group selection followed by sample selection from those groups (Figure 1).
Permutations are generated for each of the analyzed groups separately.
First, n groups are randomly selected without replacement. Then sample
selection is done by randomly selecting each of the n samples from n se-
lected groups. The procedure is repeated to obtain the second permuted
group, with the exception that samples found in the first permuted group
are explicitly filtered out. The mean estimate is thus not strongly influ-
enced by any individual groups. The lower bound of the number of unique
permutations is given by,
N |Perm3|=
(
m!
k! (m− n)!
)2
∗ nn ∗ (n− 1)k ∗ 1
2
, m>n (3.8)
A detailed diagrammatic illustration is presented in Appendix I.
Perm4
Perm4 is similar to perm3 except in the group selection step, where the
groups to be analyzed are selected followed by sampling n − 2 additional
groups without replacement. The lower bound of the number of unique
permutations is given by,
N |Perm4|= 1
2
nn(n− 1)n
(
(m− 2)!
(n− 2)! (m− n)!
)2
, m>n (3.9)
that gives 2.6e+7 permutations for an example case with m = 6 and n = 5.
Perm5
In this method, the permutation process for one of the analyzed groups is
similar to that of Perm3. The only difference is that the permutation space
for the other analyzed group is restricted to only those groups which were
used for permuting the previous analyzed group (Figure 2). This prevents
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Figure 3.5: Schematic diagram representing Perm4.
leakage of biological signal to the null distribution. The total number of
unique permutations for analyzed groups is given by,
N |Perm5|= m!
n! (m− n)! ∗ n
n ∗ (n− 1)n ∗ 1
2
, m>n (3.10)
A detailed diagrammatic illustration is presented in Appendix J.
Perm6
In this method, the permutation process for one of the analyzed groups is
similar to that of Perm4. The only difference is that the permutation space
for the other analyzed group is restricted to only those groups which were
used for permuting the previous analyzed group for the same reason as
mentioned under Perm5 (Figure 3). Total number of unique permutations
for analyzed groups is given by,
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Table 3.2: GSA methods used as reference for evaluation of mGSZm
Compared GSA
methods
Descriptions
romer Rotation testing using mean ranks [103].
GAGE Generally Applicable Gene-set Enrichment [75].
QuSAGE Quantitative Set Analysis of Gene Expression [128].
wKS
Weighted Kolmogorov-Smirnov statistics based method with empirical p-value
estimation method [114].
CAMERA
Correlation adjusted mean rank gene set test method implemented in R package
[127].
Allez
Random-set enrichment score based method implemented as R package
[88].
mGSA
Our improved version of maxmean statistics based method included in mGSZ
R package.
N |Perm6 = (m− 2)!
(n− 2)! (m− n)! ∗ n
n ∗ (n− 1)n ∗ 1
2
, m>n (3.11)
A detailed diagrammatic illustration is presented in Appendix K.
Permutation in exceptional cases
The derivations for perm2-6 are based on cases where the total number of
sample groups is more than the number of replicates in each group. Also,
the number of replicates per group was assumed to be constant for all
sample groups. The derivation and explanation of a permutation method
for exceptional cases is presented in Appendix L.
3.2.2 Reference GSA methods used in evaluation,
The evaluation of mGSZm was based on comparison of results generated
with mGSZm and seven other popular GSA methods presented in Table
3.2.
3.2.3 Datasets used in evaluation
mGSZm was intended for GSA of multi-group data with fewer than six
replicates per group. Therefore, multi-group datasets were used in the
evaluation of the method. Also, as one of the evaluations was based on
data splitting where we use the method to analyze smaller (test) and larger
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(reference) subsets of the data and evaluate the method based on its per-
formance on test subset as compared to reference subset (Section ??), two
of the used datasets have a minimum of 15 biological replicates.
Human primary cell data
Human primary cell gene expression data was downloaded from the Gene
Expression Omnibus data repository (GEO accession: GSE49910). A to-
tal of 124 arrays of Affymetrix Human Genome U133 Plus 2.0 expression
arrays were downloaded. The dataset consists of eight sample groups of
different cell types - embryonic stem cells, tissue stem cells, epithelial cells,
fibroblasts, endothelial cells, osteoblasts, keratinocytes and smooth muscle
cells. The evaluation of the methods was based on analysis of the sample
groups that have at least 15 biological replicates, are well clustered and
have no outliers (endothelial cells and keratinocytes).
Breast cancer data
Breast cancer data was downloaded from the Gene Expression Omnibus
data repository (GEO accession GSE3165). The data includes 94 arrays
of platform GPL887 (Agilent Human 1A Microarray V2) with six sample
groups corresponding to six molecular subtypes of breast cancer. The sub-
types are basal-like, luminal A, luminal B, Her2, normal-like and claudin-
low. The evaluation of the methods was based on comparison of the sample
groups that have at least 15 biological replicates, are well clustered and have
no outliers (Basal-like and Her2).
Mouse tissue gene expression data
Mouse tissue specific gene expression data was downloaded from the Gene
Expression Omnibus data repository (GEO accession GSE9954). The data
is based on Affymetrix Mouse Genome 430 2.0 Array and consists of ex-
pression profiles from six mouse tissues (kidney, liver, lung, heart, muscle
and adipose). The dataset consists of four replicates for kidney and three
replicates for each of the rest of the tissues.
Gene sets
Curated gene sets from the Molecular Signatures Database were used [114].
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3.2.4 Evaluation of permutation methods
The evaluation of permutation methods was done with a novel approach
based on data splitting, where the smaller subset is used to test methods
and the bigger subset (the rest of the data) is used to generate reference
gene sets.
Identification of reference gene sets based on data splitting
The data splitting method partitions a big gene expression dataset into test
and reference subsets (Figure 3.6) and thus requires a dataset with a large
number of replicates per group. After splitting, the test and reference parti-
tions comprise 25 % and 75 % of the data (arrays), respectively. Reference
gene sets were generated by taking the union of the top most significant
gene sets (for example, 5) reported by each of the compared methods for
the reference data. Possible bias due to the selection of a number of top
gene sets was minimized by repeating the procedure for multiple numbers
of top most significant gene sets, for example, 3,5 and 7. The evaluation
of the compared gene set analysis methods was based on the cumulative
count of reference gene sets in the top, for example, 20 gene sets returned
by each of the methods. The cumulative counts at each rank were the
average of counts obtained across different runs with a different number
of top gene sets of reference data. The procedure was repeated multiple
times (for example 100 depending on the test) for different data splits and
the cumulative counts were averaged over all the runs. The results were
presented as a plot of the averaged cumulative counts.
Permutation methods were implemented with GSZ and their evaluation was
based on the ability of the methods to identify reference gene sets generated
with data splitting method described above using human primary cell data
and breast cancer data (Section 3.2.3).
3.2.5 Evaluation of mGSZm
mGSZm was evaluated with three different methods:
Identification of reference gene sets based on data splitting
Similar to the evaluation of permutation methods, mGSZm was also evalu-
ated based on its ability to identify reference gene sets generated with data
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Figure 3.6: Evaluation based on data splitting. Workflow of the evaluation
based on splitting of data.
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splitting method using human primary cell data and breast cancer data
(Section 3.2.3)
Identification of tissue specific gene sets
Genes that are functional and thus expressed in specific tissues only are
called tissue specific genes. Tissue specific genome-wide gene expression
data can be a useful tool for evaluating gene set analysis methods, be-
cause a considerable number of studies on tissue specific gene expression
exist [80], [25]. Tissue specific gene sets were generated using tissue spe-
cific genes identified and verified by previous studies [110]. As gene sets
available from various sources might contain a certain amount of noise (ir-
relevant genes), different proportions of noise were also introduced to the
tissue specific gene sets. This was done by randomly selecting x% (where
x(0,10,20,30,40,50,60,70,80,90)) of genes in a tissue specific gene set and re-
placing them with randomly selected genes from the remaining data. This
procedure gives 10 gene sets for each tissue type with noise level varying
from 0% to 90%. These gene sets can then be mixed with randomized gene
sets containing other genes in the analyzed dataset. mGSZm was evaluated
based on its ability to rank tissue specific gene sets higher than the random
gene sets as compared to reference GSA methods. Pairwise comparisons
between all possible tissues were done and results were presented as the
average cumulative count of tissue specific gene sets in top 50 gene sets.
False positive test
mGSZm was evaluated for its ability to control the false positive rate (type
1 error) by investigating the p-value distribution of gene set scores from
null gene expression data. Null gene expression data was generated by ran-
domizing the sample labels of the analyzed gene expression data. P-values
estimated by mGSZm or similar methods based on null gene expression
data with no true differential gene expression should follow a uniform dis-
tribution.
3.3 Gene Set Analysis of genome-wide methyla-
tion data
Gene set analysis has become standard practice among various omics meth-
ods [85]. However, for datasets other than gene expression, such as DNA
methylation data, over-representation analysis is more popular [53, 129, 92,
23]. The approach involves the generation of a list of the most interesting
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CpG sites based on some threshold such as p-values for differential methy-
lation scores. The list of CpG sites is reduced to a list of genes with several
ad hoc methods such as including genes with one or more CpG site(s) an-
notated to the gene significantly associated with respective studied pheno-
typic trait [104]. One of the major limitations of these methods is that the
results vary with varying thresholds used to select the list of the most inter-
esting CpG sites. Another major limitation of over-representation analysis
of methylation data is that genes with a larger number of CpG sites within
their genomic region have a higher probability of having at least of CpG
with significant difference in methylation based on a threshold. Such genes
are more likely to end up in a list of differentially methylated genes and
consequently lead to biased pathway analysis results. This phenomenon
has been shown by [39].
The problem of ambiguity in results due to ambiguous thresholds used to
select the CpG list is addressed by hunctional class scoring methods based
on signal summary and ranked list, as whole genome-wide DNA methyla-
tion at gene level data is analyzed (Section 1.2.3). CpG level genome-wide
DNA methylation data can be summarized to gene-level genome-wide DNA
methylation by several approaches, such as taking the average of the methy-
lation levels of all CpGs mapping to the genomic region of a gene or using
the methylation level of a CpG with maximum difference in methylation
level between compared groups as a proxy for gene level methylation. My
third contribution is the application of such methods for gene set analysis of
methylation data to investigate epigenetic signatures of smoking at biolog-
ical pathway level (Publication III). Gene set analysis of DNA methylation
data shifts the analysis from the level of individual CpG sites to gene sets
level. The outcome is the understanding of potential biological significance
of the methylation changes caused by smoking. This approach enhances
the statistical power of test of association between smoking and methy-
lation by pooling methylation levels of a set of genes linked to the same
biological pathways. The GSZ-based gene set analysis method published
in Publication I was applied for the analysis. We analyzed gene sets from
the Molecular Signature Database (MSigDB), a collection of gene sets from
various annotation libraries such as Gene Ontology [5], KEGG pathways
[56] and reactome [28].
CpGs were mapped to biological pathways via gene annotations. CpGs
mapping to any genomic region of the corresponding genes (TSS200, 0-200
bases upstream of the transcriptional start site; TSS1500, 200-1500 bases
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upstream of the TSS; 5’UTR, within the 5’ untranslated region, between
the TSS and the ATG start site; Body, between the ATG and stop codon
irrespective of the presence of introns, exons, TSS, or promoters; 3’UTR,
between the stop codon and poly A signal) were considered as candidate
proxy for gene level methylation level. As CpG sites from different regions
of a gene were considered as proxy for the gene level methylation, spec-
ulation on whether the altered methylation activates or deactivates gene
expression is inconclusive and thus outside the scope of this work. How-
ever, it is important to note that the function of DNA methylation varies
with different genomic contexts [54].
3.3.1 Study population
The Cardiovascular Risk in Young Finns study (YFS) is a prospective
multi-centre study initiated in 1980 (number of subjects=3596, baseline age
3-18 years). The participants have been followed up over 40 years to investi-
gate childhood risk factors for cardiometabolic outcomes in adulthood [98].
The follow-up includes comprehensive data collection using questionnaires,
physical measurements, dietary interviews and blood tests from childhood
to young adulthood. This study was based on a subset of 192 participants
for whom DNA methylation measurements from whole-blood samples were
available from the 2011 follow-up. The smoking history of the partici-
pants was self-reported and belonged to six categories based on smoking
frequency (1. active smoker or at least once a day, 2. once a week or more
often, however not daily, 3. less often than once a week, 4. attempts to
quit, 5. has quit, 6. has never smoked). To obtain maximum effect size,
the study was focused on sub-sample of 125 participants, 40-49 years of
age who were either active smoker (n=21) or have never smoked (n=104).
The study has been approved by the ethical committee of the Hospital
District of Southwest Finland and the Regional Ethics Committee of the
Expert Responsibility area of Tampere University Hospital. All subjects
have given informed written consent.
3.3.2 DNA methylation assessment
DNA was extracted from 192 EDTA-blood samples usingWizardAˆ®Genomic
DNA Purification Kit (Promega Corporation, Madison, WI, USA) accord-
ing to the manufacturer’s instructions. Genome-wide quantification of DNA
methylation levels was done using Illumina Infinium HumanMethylation450
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BeadChips [15], [14], [13] in the Core Facility at the Institute of Molecular
Medicine Finland (FIMM), University of Helsinki following manufacturer’s
protocols. The HumanMethylation450 BeadChip measures DNA methyla-
tion at more than 485,000 CpG cites across the genome. The arrays were
imaged with a high-precision scanner (iScan system, Illumina Inc.), and the
signal intensities were extracted using a software package (GenomeStudio
Software, Illumina Inc.).
3.3.3 Data pre-processing
Data was obtained and processed from raw methylation image files using
the minfi package in R/Bioconductor [4]. Samples with the sum of detection
P-values across all the probes above 0.05 were excluded from the analysis.
Samples in which the log2 median of methylated and unmethylated inten-
sities did not cluster within the default cutoff (10.5) in the getQC function
in minfi were filtered out. Further, samples for which the real sex did not
match the predicted sex with the getSex function in minfi were excluded.
Background subtraction and dye-bias normalization were performed via the
noob method [120] implemented in minfi. Further, stratified quantile nor-
malization was performed using the preprocessQuantile function in minfi.
Probes with detection P-value above 0.01 in 99% of the samples were fil-
tered out. CpG loci on sex chromosomes were excluded from the analysis
to avoid gender based methylation bias. Also, cross-reactive probes and
probes with single nucleotide polymorphisms (SNPs) were excluded from
the analysis. After quality control, the total number of autosomal CpGs
was 429,773. Similarly, the total number of samples was reduced to 186
which included 21 active smokers, 104 non-smokers, 58 former smokers and
3 with no smoking information. As the focus of this study was to investi-
gate pathway level methylation changes induced by smoking, we excluded
former smokers from the analysis for maximal effect size. Batch correction
based on control probes removes technical artifacts in the data. This was
done by adding first two principal components of control probes as covari-
ates in the linear model during CpG-wise differential methylation analysis
between active smokers and non-smokers.
3.3.4 Gene set analysis
Differential methylation analysis
All statistical analyses were performed using R (v.3.3.2) [97] based on M-
values, the log2 ratio of the intensities of methylated probe versus unmethy-
lated probe. Differentially methylated CpG loci with respect to smoking
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status were identified using multivariate linear regression implemented in
the CpGassoc R package [8]. All analyses were adjusted for age, sex, bmi,
technical covariates (chip and array), white blood cell type proportions and
the first two principal components of array control probes. The fraction of
white blood cells (CD8T, CD4T, NK cells, B cells, monocytes, and granu-
locytes) was estimated through the reference-based Houseman method [49]
using the estimateCellCounts function in the minfi package. Adjustment for
cell composition was done by including the six estimated cell type fractions
as covariates in the multivariate linear regression. Differential methylation
scores (t-statistic) for genes were identified by utilizing as a proxy the CpG
site with maximum absolute t-score from any genomic regions in relation to
the genes. Since the mechanism how methylation influences gene expression
is not completely understood, we limit this study only to the identification
of smoking related methylation patterns within the genomic region of a
gene, be it coding or promoter region. The annotation database provided
by Illumina was utilized to connect the CpG sites to the genomic identifiers
[46].
mGSZ analysis
Gene set analysis was performed to understand smoking induced alteration
in DNA methylation at biological process or pathway level. The analysis
was performed using the gene set analysis method implemented in mGSZ
package in R [82]. Similar to gene set analysis of gene expression data,
gene-gene correlation needs to be considered also in DNA methylation data
analysis as CpGs are correlated just like genes are. The correlation among
CpGs have been shown to increase as the proximity between CpGs increase
[111]. mGSZ estimates a p-value for gene set scores based on the permuta-
tion of sample labels instead of genes. This approach keeps the gene-gene
correlation structure intact and thus prevents false positive results (Sec-
tion 1.2.5). GSA methods based on gene permutation assume that genes
are independent, leading to spurious results [41]. Gene sets were down-
loaded from the Molecular Signatures Database (MSigDB) [114], [69]. The
database contains a collection of 22569 gene sets as of September 21, 2019,
categorized into eight major categories based on sources and method of
generation: hallmark, curated, positional, motif, computational, gene on-
tology, oncogenic and immunogenic signatures.
Chapter 4
Results and discussion
4.1 Asymptotic p-value estimation
This study introduces an asymptotic method of p-value estimation for com-
petitive gene set analysis in Publication I [82]. The asymptotic p-value is
estimated by using an approximation of the true distribution. In the case of
GSA, the distribution of gene set scores calculated from set of all possible
permutations represents the true null distribution. The P-value is then es-
timated from the cumulative distribution function of the fitted distribution.
This approach requires fewer permutations to estimate p-values with bet-
ter resolution than 0.001 as returned by popular permutation based GSA
methods. Thus, the approach significantly speeds up the gene set analysis
process. Knijnenburg et al., [59] proposed a similar method for p-value
calculation. It, however, requires more permutations than our proposed
method.
Publication I investigates whether or not GSZ scores can be modelled by
any known statistical distributions. We chose the extreme value distri-
bution (EVD), general extreme value distribution (GEVD), gamma and
normal distributions as candidates. The gamma and normal distributions
were chosen as controls. GSZ scores for each gene set were calculated 500
times with 500 sample (or array) permutations of the original data. Sam-
ple permutations were done to nullify the biological effect in the data. The
distributions were fitted to the empirical null distribution of the gene set
scores. Distributional parameters were estimated from the fitted models
and P-values were calculated from the cumulative distribution function.
We refer to the p-values calculated from the fitted distributions as asymp-
totic p-values.
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This section presents results from the evaluation of asymptotic p-values
with two datasets: 1) P53 cancer data, and 2) gender data. Asymptotic
p-values calculated with 500 sample permutations were evaluated against
empirical p-values calculated from 100000 sample permutations (the ref-
erence of truth) (Section 3.1.5). Empirical p-values calculated with 500
sample permutations were used as a negative control. Results are pre-
sented as negative log10 p-values and thus the higher the value, the lower
the pvalue. This transformation was done in order to make visualization of
the plots easier.
4.1.1 Evaluation of asymptotic p-values
Results from p53 cancer data
Empirical p-values calculated with 500 permutations failed to accurately
determine p-values smaller than 1/500 (green dots in Figure: 4.1) because
the minimal obtainable empirical p-value depends on the number of per-
mutations. P-values obtained from a Gaussian model fitted to GSZ scores
failed suggesting that the model is not appropriate for GSZ scores which
are extreme values (black dots in Figure: 4.1). P-values obtained from the
extreme value (EVD) and general extreme value (GEVD) distributions fit-
ted to mGSZ scores were the best estimates (red and blue dots in Figure
4.1), with the best correlation and mse scores (Table 4.1). This is expected
because, based on the calculation, GSZ is the highest absolute value in a
profile generated from subsets of ranked gene list by applying subsequent
threshold at each gene position (Section 1.2.4). EVD was chosen as the
most optimal model for the null distribution of GSZ scores, because the
mean squared error when compared with the “reference of truth” was the
smallest for EVD (Tables 4.1). Thus, the results suggest that EVD models
the null distribution of GSZ scores from permuted data accurately, allowing
the end users to make accurate p-value estimation with data having as few
as three biological replicates.
Similarly, in the case of mGSA, EVD turned out to be the best model
(Appendices A and B). As expected in the case of mAllez, which is sum
based gene set score, NORM is the best model (Appendices A and C).
Notice that empirical p-values based on 500 permutations fail with mGSA
and mAllez.
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Figure 4.1: Scatter plot of asymptotic p-values (EVD, GEVD, GAMMA
and NORM) (X-axis) estimated from 500 sample permutations against the
reference p-value (Y-axis). The reference p-value corresponds to empiri-
cal p-values estimated from 100000 sample permutations. Green dots are
empirical p-values calculated with 500 sample permutations and represent
negative control. Data - P53 cancer data. Abbreviations: EVD, Extreme
Value type I Distribution; GEVD, General Extreme Value Distribution;
GAMMA, Gamma distribution ; NORM, Normal distribution; Empirical,
Empirical distribution.
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Table 4.1: Correlation (cor) and mean squared error (mse) of asymptotic
p-values estimated from statistical distribution models fitted on the null dis-
tribution of GSZ scores generated with 500 sample permutations against
reference p-values generated with 100000 sample permutations with p53
data. The analysis was performed with whole gene sets list as well as sub-
set of biologically interesting regions (p -values < 0.10). Scores not meeting
the criteria (Section 3.1.5) for optimal model are highlighted. Abbrevia-
tions: EVD, Extreme Value type I Distribution; GEVD, General Extreme
Value Distribution; GAMMA, Gamma distribution ; NORM, Normal dis-
tribution; Empirical, Empirical distribution; mse, mean squared error; cor,
Pearson correlation.
Method Models mse mse(subset) cor cor(subset)
mGSZ EVD 0.005 0.03 0.99 0.99
GEVD 0.02 0.09 0.99 0.99
GAMMA 0.07 0.36 0.98 0.98
NORM 1.68 10.65 0.89 0.95
Results from gender data
The lowest GSZ score p-value obtained from gender data is ˜0.001. Whereas,
the one with p53 cancer data is ˜0.00001. This difference between the
datasets is interesting as it clearly illustrates when the empirical approach
for p-value estimation fails. For example, in contrast to the results from
p53 data, empirical p-values calculated with 500 permutations are equally
good as asymptotic p-values calculated with EVD and GEVD (Figure: 4.2)
(Table 4.2). This is because the lowest p-value is achievable already with
500 sample permutations. Similar results were observed with mGSA and
mAllez (Appendices D, E and F).
4.1.2 Evaluation of mGSZ
The performance of mGSZ was evaluated by comparing results generated
by mGSZ with that generated by state-of-the-art methods that are available
as R packages.
Comparison of mGSZ with program packages
The performance of mGSZ was compared to that of GSA [34]), Allez ([88],
CAMERA [127] and ROAST [126]. We also included mGSA and mAllez
in the comparison to show the improved performance as compared to their
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Figure 4.2: Scatter plot of asymptotic p-values (EVD, GEVD, GAMMA
and NORM) (X-axis) estimated from 500 sample permutations against the
reference p-value (Y-axis). The reference p-value corresponds to empiri-
cal p-values estimated from 100000 sample permutations. Green dots are
empirical p-values calculated with 500 sample permutations and represent
negative control. Data - Gender data. Abbreviations: EVD, Extreme
Value type I Distribution; GEVD, General Extreme Value Distribution;
GAMMA, Gamma distribution ; NORM, Normal distribution; Empirical,
Empirical distribution.
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Table 4.2: Correlation (cor) and mean squared error (mse) of asymptotic
p-values estimated from statistical distribution models fitted on the null
distribution of GSZ scores generated with 500 sample permutations against
reference p-values generated with 100000 sample permutations with gender
data. The analysis was performed with whole gene sets list as well as subset
of biologically interesting regions (p -values < 0.10). Scores not meeting the
criteria for optimal model are highlighted. Abbreviations: EVD, Extreme
Value type I Distribution; GEVD, General Extreme Value Distribution;
GAMMA, Gamma distribution ; NORM, Normal distribution; Empirical,
Empirical distribution; mse, mean squared error; cor, Pearson correlation.
Method Models mse mse(subset) cor cor(subset)
mGSZ EVD 0.002 0.03 0.99 0.99
GEVD 0.002 0.03 0.99 0.99
GAMMA 0.003 0.05 0.99 0.98
NORM 0.03 0.73 0.96 0.99
original versions, GSA ( Efron and Tibshirani, 2006 ) and Allez ( Newton
et al. , 2007). The comparison was based on three tests: (i) Detection of
relevant gene sets, (ii) False-positive signal test and (iii) P-value test where
we compare the log p-values reported by each of the compared methods.
We summarize the results in Table 4.3. Two datasets (p53 and gender)
were used for all evaluation tests except for false positive signal analysis.
For false positive signal analysis, the leukemia dataset was used. As 79.9 %
of the individual genes are differentially expressed in the leukemia data [30],
it is an ideal data to test the tendency of methods to generate false positive
results. Competitive gene set analysis methods compare genes in a gene set
with genes not in gene sets. So, a large proportion of differentially expressed
genes should not result in a large number of differentially expressed genes
sets. CAMERA showed the best results in false positive signal analysis.
However, in the remaining two evaluation tests, mGSZ outperformed the
other methods.
False positive signal test The false positive signal test shows that
mGSZ and most other methods show quite similar behavior (Figure 4.3).
While CAMERA is the most conservative, ROAST shows a strong noise
signal (Figure 4.3). The result points out a major difference between
competitive and self-contained gene set analysis methods. Self-contained
gene set analysis methods calculate the gene set scores without considering
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Table 4.3: Summary of results from various evaluation tests performed for
comparison of mGSZ, mGSA, mAllez with the program packages. Num-
bers indicate approximate rank of the methods based on the test results.
Asterisk sign indicates that a test is not applicable to a particular method.
Evaluations Data mGSZ mGSA GSA mAllez Allez CAMERA ROAST
Detection of
relevant gene
sets
p53 1 2 3 6 7 4 5
Gender 1 4 6 5 7 2 3
P-value
resolution
p53 1 2 6 3 * 4 5
Gender 1 3 4 2 * 5 6
False positive
signal analysis
Leukemia 2 2 2 2 * 1 6
genes other than member genes. Thus, in a signal rich dataset like the
leukemia dataset, most of the null gene sets are reported as significant by
self-contained gene set analysis method like ROAST.
Detection of relevant gene sets The evaluation was done with p53,
gender and TF datasets. In the case of the p53 dataset, the top fifty gene
sets reported by each of the compared methods from P53 were pooled. Each
of the pooled gene sets was then analyzed separately for their relevance to
p53 activity. A total of forty gene sets highly relevant to p53 activity
were selected as relevant gene sets for p53 data (Appendix G). In the case
of the gender dataset, the top twenty gene sets reported by each of the
compared methods were pooled. Each of the pooled gene sets were then
analyzed separately for their relevance to gender. A total of ten gene sets
highly relevant to gender were selected as relevant gene sets for gender data
(Appendix H). Methods were compared for the number of relevant gene sets
in the top n (50 in P53 data and 20 in gender data) gene sets reported.
The results are presented as a cumulative count plot. The plot represents
the number of relevant gene sets on y-axis and top n gene sets on x-axis.
Based on results from p53 and gender data with mGSZ, mGSA, mAllez
and the program packages, mGSZ is clearly the best method (Figure 4.4a
and 4.4b). Moreover, mGSA and mAllez show improved performance as
compared to GSA and Allez (Figure 4.4a and 4.4b).
P-value test mGSZ reports the best p-values (based on resolution) with
the p53 dataset for the top 50 gene sets as compared to the other methods
(Figure 4.5a). However, in case of the gender dataset, mGSZ reports the
best p-values for the upper region of the gene list and then slightly lags
behind mGSA, mAllez and ROAST in the lower region of the gene list
(Figure 4.5b).
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Figure 4.3: Comparison of mGSZ with the program packages with random-
ized gene sets.
(a) P53 data (b) Gender data
Figure 4.4: Relevant gene sets identified by the compared methods. Figures
represent cumulative count of biologically relevant gene sets (Apendices G
and H) over the ranked list of top 50 gene sets in case of the p53 data
and top 20 gene sets in case of the gender data reported by each of the
compared methods. mGSZ (black) shows the best performance.
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(a) P53 data (b) Gender data
Figure 4.5: Log p-values for the top 50 gene sets estimated by each of the
compared methods in p53 and gender datasets.
4.2 Advanced Permutation method
The problem of accurate p-value estimation with a smaller subset of per-
mutations was addressed by introducing an asymptotic p-value estimation
method in Publication I [82]. However, at least six replicates per group is
recommended for reliable results. With smaller data, the number of obtain-
able permutations is not sufficient to generate an accurate null distribution.
Multi-group (meaning data with > 2 groups in this thesis) gene expression
data with fewer than six replicates are common due to various resource
constraints. Naive application of sample label permutation for p-value es-
timation is potentially unreliable. We developed and evaluated advanced
permutation methods for gene set analysis of such datasets (Publication II).
4.2.1 Evaluation of permutation methods
Perm3-6 showed similar performance in evaluations and therefore, for clar-
ity, we only present results for Perm 4 in detail in this chapter. Perm1, the
naive permutation method was the worst performing method with both
datasets (Figure 4.6). Perm4 reported ∼ 8 (average over 20 different data
splits) more relevant gene sets at rank positions 27 to 33 in breast can-
cer data and 46 to 50 in primary cell data. Perm2 showed similar results,
however, we prefer Perm4 to Perm2 because Perm2 is the least constrained
permutation method and it cannot prevent biological signal leakage into
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Figure 4.6: Plot showing cumulative count of reference gene sets (y-axis)
across ranked list of top 50 gene sets (x-axis) for evaluation of permutation
methods. Results from three gene set analysis methods based on three
different permutation methods with two different datasets; 1) Breast cancer
data, 2) Human primary cell data are presented.
the null distribution.
4.2.2 Evaluation of mGSZm
Perm4 was selected as the most appropriate permutation method based on
evaluation presented in Section 4.2.1. Thus, mGSZm is based on imple-
mentation of perm4 in mGSZ. We evaluated the new method by comparing
its performance with seven popular gene set analysis methods (Table 3.2)
using three different evaluation methods (Section 3.2.5).
Identification of relevant gene sets
mGSZm was compared with seven other methods based on the identifica-
tion of reference gene sets generated with the data splitting method ex-
plained in Section ??. Results from both breast cancer and human pri-
mary cell datasets rank mGSZm as the best method (Figure 4.7). The
performance of CAMERA is close to that of mGSZm in Breast cancer and
QuSAGE has similar performance to that of mGSZm in human primary
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Figure 4.7: Comparison of mGSZm with seven other popular gene set anal-
ysis methods based on the cumulative count of reference gene sets (y-axis)
identified across the ranked list of top 50 gene sets (x-axis). Results from
two different datasets are presented; 1) Breast cancer data, 2) Human pri-
mary cell data.
cell data. However, while performance of mGSZm is consistent with both
datasets, CAMERA and QuSAGE performs better in one but fails in the
other dataset (Figure 4.7). GAGE reported about one gene set more than
mGSZm at rank positions 4 to 15, however the performance of the methods
dropped clearly at the rest of the rank positions in primary cell data.
Identification of tissue specific gene sets
mGSZm was also evaluated with seven other gene set analysis methods
based on its ability to identify tissue specific gene sets as explained in
Section 3.2.5. mGSZm, Allez and QuSAGE performed similarly well in
this evaluation test (Figure 4.8). Inconsistencies in performance of the
other compared methods are also clear in this evaluation. For example,
CAMERA, which was a close competitor to mGSZm in other evaluations, is
one of the worst performers in this evaluation. Further, Allez and QuSAGE,
which are close competitors to mGSZm in this evaluation, performed weakly
in other evaluations (Figure 4.7).
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Figure 4.8: Cumulative count of tissue specific gene sets (y-axis) across
ranked list of top 50 gene sets returned by eight compared gene set analysis
methods. Figure represents average cumulative count of tissue specific gene
sets over the ranked list of top 50 gene sets reported by each of the compared
methods in 15 pairwise comparisons of six different tissue samples.
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Figure 4.9: Distribution of p-values obtained from mGSZm and six other
compared gene set analysis methods with null gene expression data.
Generation of type 1 error
To ensure that mGSZm is not generating false positive results due to the
implementation of perm4, we tested mGSZm along with six other gene set
analysis methods with null gene expression data. The null gene expression
data was generated by randomizing the sample labels of breast cancer gene
expression data. Allez was excluded from the evaluation as it does not
report P-values. P-values for QuSASE were calculated using the pdf.pVal
function in the R/Bioconductor package, qusage. As there is no true differ-
ential gene expression in null data, p-values generated by an ideal method
should follow a uniform distribution. P-values generated by mGSZm fol-
lowed an approximately uniform distribution, suggesting that mGSZm is
fairly conservative in the generation of type 1 errors (Figure 4.9). The
P-value distributions of most other methods showed similar distributions
except QuSAGE, which is heavily skewed to the left.
4.3 Gene Set Analysis of genome-wide methyla-
tion data
Currently, gene set analysis of genome-wide DNA methylation data is pre-
dominantly based on over-representation analysis [53, 129, 92, 23] despite
the limitations of the approach related to an ambiguous threshold for se-
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lecting the list of interesting CpG sites and differential representation of
CpGs in genes [39]. Study III of this thesis was based on gene set anal-
ysis of genome-wide DNA methylation data with mGSZ, a modern signal
and ranked list based second generation method developed in study I [82].
mGSZ is threshold-free method and thus addresses the problem related to
ambiguous thresholds by utilizing whole genome-wide methylation data at
the gene level. Methylation levels of CpGs were summarized to gene level
by using as proxy the methylation level of CpG within the genomic region
of a gene that had maximum absolute t-statistic in differential methyla-
tion analysis between active smokers and non-smokers (Section 3.3.4). The
novel gene set analysis in this study identified smoking related methylation
changes in several novel biological pathways described below.
Among eight major gene set collections in MSigDB, significant results
(FDR ≤ 0.05) were obtained from three - Hallmark, Curated and Gene
Ontology (Table 4.4). Results are presented as alterations in methylation
patterns in genomic regions associated with biological pathways. Details
on hypo- or hyper-methylation is not discussed as the analysis is based on
CpGs mapping to any genomic region such as coding or promoter.
4.3.1 GO based gene sets
Eight gene ontology based gene sets were identified to have altered methy-
lation due to smoking. The sense of smell is regulated by several biological
processes such as tobacco-induced sinonasal inflammation and squamous
cell metaplasia [95]. Unlike other neural tissues, the olfactory epithelium
undergoes constant renewal through exfoliation of aged cells and genera-
tion of new ones from stem cells [21]. The division and differentiation of
the stem cells are regulated by epigenetic mechanisms [43]. The altered
methylation pattern (hypermethylation) in genomic regions responsible for
olfactory and related G protein coupled receptor activities and pathways
identied in this study supports the theory (Tables 4.4). Despite the un-
derstanding that smoking is associated with olfactory and gustatory dys-
function, previous studies failed to identify these pathways which could be
due to the usage of ORA methods. This study identified a novel biological
pathway related to the olfactory system among others in DNA extracted
from whole blood, highlighting the importance of the functional class scor-
ing class of GSA methods, which take into account the complete gene list
with weights based on the magnitude of the effect.
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Smoking has been shown to activate embryonic signalling pathways such
as the hedgehog signalling pathway [65]. Smoothened is a protein encoded
by SMO gene that plays a role in the hedgehog signalling pathway for cell
differentiation. The protein belongs to the class of G protein-coupled re-
ceptors. Our results suggest that smoking alters the methylation pattern
(hypomethylation) in genes involved in the regulation of the smoothened
signalling pathway. We have also identified smoking related altered methy-
lation (hypermethylation) in genes involved in thrombin activated receptor
activity. Thrombin receptor activity is related to platelet function and
thus plays a role in thrombosis. Active smoking also seems to alter methy-
lation (hypomethylation) in genes involved in semaphorin receptor activity
which plays an important role in the developing nervous system [99]. Simi-
larly, genes involved in AP-2 adaptor complex binding are hypermethylated
among active smokers of this study. The AP-2 adaptor complex mediates
endocytosis which has been shown previously to be affected by smoking [33].
This study pinpoints potential epigenetic mechanism underlining the effect
of smoking on endocytosis. This study identified smoking related methy-
lation changes in several G-protein coupled receptor related pathways de-
scribed above. These are family of proteins that couple with G protein and
activate cellular responses to external molecules. Compounds secreted into
blood by smoking stimulate the secretion of catecholamine and serotonin.
These compounds act on platelets with the help of G protein-coupled re-
ceptors, altering the normal functionality of platelets which leads to condi-
tions like thrombosis [73]. Based on the results, we speculate that smoking
stimulates G-protein coupled receptor activity through altered methylation
(hypermethylation). Similar results were presented by [45].
4.3.2 Curated gene sets
Four curated gene sets were identified to have smoking related alteration in
methylation patterns. Cigarette smoke contains compounds that activate
the aryl hydrocarbon receptor (AHR) [113]. The activation has been shown
to mediate chronic inflammation and cancer [78]. Our results pinpoint a
potential epigenetic mechanism involved in AHR activation. Acidic and
rich in cysteine (SPARC) is a secreted protein expressed in several cancers.
It has been shown that down regulation of SPARC in glioma cells is asso-
ciated with decreased tumor cell survival [108]. Smoking related alteration
in the methylation pattern in SPARC and related genes as identified in this
study and shown by others [36] provides insights into the epigenetic basis of
smoking effects on cancers. RORA (retinoic acid-related orphan receptor),
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a protein that plays an important role in gene regulation, is highly expressed
in Chronic obstructive pulmonary disease patients. The gene is known to
contribute to emphysema as well as to lung cancer [109]. The finding of
methylation changes in genes associated with RORA activation perhaps
indicates epigenetic mechanism of smoking related changes in the pathway.
Isomers of retinoid receptors - retinoic acid receptor (RAR) and retinoid X
receptor (RXR) - are transcription factors important for lung tissue main-
tanence and repair. The receptors have inhibitory effects on non-small cell
lung cancer cell growth [16]. A study has shown that smoking diminishes
retinoid acid signalling in lungs [123]. Based on this study, genes related to
RARRXR pathway are hypermethylated among smokers, supporting the
hypothesis that this could down-regulate the pathway activity as shown by
other studies.
4.3.3 Hallmark gene sets
The gene set “UV response down” contains genes that are down-regulated
by ultraviolet radiation. Ultraviolet radiation has been previously shown
to affect DNA methylation [6]. Interestingly, active smoking seems to affect
genes that are sensitive to ultraviolet radiation and this is the first report
of such a finding in our knowledge which suggests that active smoking and
ultraviolet radiation activate a common pathway.
4.3.4 Results adjusted for alcohol usage and socioeconomic
status
Alcohol usage [124] and socioeconomic status [79] have been shown previ-
ously to have an effect on DNA methylation. This section presents results
of active smoking on DNA methylation adjusted for alcohol usage and so-
cioeconomic status in addition to the covariates mentioned in Section 3.3.4.
However, 16 out of 125 participants did not have information on alcohol us-
age and socioeconomic status. The number of active smokers in the analysis
was reduced from 21 to 16 because of missing information on socioeconomic
status. Alcohol consumption was measured by asking participants to report
their alcohol consumption during the previous week. One unit is equivalent
to 14 g of alcohol [55]. Socioeconomic status was based on occupation and
was categorized as manual, lower non-manual and upper non-manual. As
reduction in sample size due to the additional covariates is likely to reduce
the statistical power, we chose to report findings with FDR≤ 0.25 as signif-
icant. Note that FDR≤ 0.25 is a commonly used threshold for significant
finding in exploratory analyses such as gene set analysis.
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Table 4.4: List of gene sets from Molecular Signature Database identified
in this study with FDR ≤ 0.05.
Number
of
findings
Significant
gene sets
Number
of
genes
GSZ-
score
P-value FDR
Related previous
findings
Gene Ontology (GO) based gene sets
1.
Regulation of smoothened
signaling pathway involved
in dorsal ventral neural tube
(biological process)
8 4.89 5.12e-06 0.04
Related to G-protein
coupled receptor
[45].
2.
Thrombin activated receptor
activity (molecular function)
5 4.27 2.3e-05 0.03
Related to G-protein
coupled receptor
[52].
3.
Protein domain specific
binding (molecular function)
657 4.75 5.7e-05 0.03 [64]
4.
Olfactory receptor activity
(molecular function)
321 9.96 6.09e-05 0.03 Novel finding
5.
Semaphorin receptor activity
(molecular function)
9 4 6.85e-05 0.03
Involved in axonal
guidance
[116]
6.
AP-2 adaptor complex binding
(molecular function)
7 4.22 1.15e-04 0.03
Active smoking affects
endocytosis
[33].
7.
Nuclear receptor activity
(molecular function)
45 4.81 1.18e-04 0.03
[91],
[101]
8.
G-protein coupled receptor
activity (molecular function)
725 7.21 2.28e-04 0.05 [53]
Curated gene sets
9.
Aryl hydrocarbon receptor
signalling (canonical reactome)
7 5.76 6.27e-07 0.003 [101]
10.
SHI SPARC targets up
(chemical and genetic
perturbations)
22 5.86 1.22e-06 0.003 [36]
11.
RORA activates gene
expression (canonical reactome)
17 4.99 1.68e-05 0.03 [109]
12.
RARRXR pathway
(canonical, biocarta)
7 4.38 3.41e-05 0.05 [102]
Hallmark gene sets
13. UV response down 138 4.50 0.001 0.05 Novel finding
The novel finding of this study - smoking related altered methylation in
olfactory system - was retained also after adjusting for alcohol usage and
socioeconomic status of the participants with FDR ≤ 0.25 (Table 4.5). The
well established effect of smoking on aryl hydrocarbon receptor signalling
is also retained with FDR of 0.004. Similarly, the effect of smoking on UV
sensitive genes as well as four other pathways with gene regulatory effect
were retained (Table 4.5).
4.3.5 Strengths, limitations and future direction of the study
To our knowledge, this is the first study to perform second generation gene
set analysis of genome-wide methylation data. The approach identified
several novel biological pathways with epigenetic signatures induced by
active smoking. A major limitation of the study was the sample size, due
to which the significant findings were limited to only 13 biological pathways.
An ideal sample size for novel findings with a novel approach like this would
be similar to the study by [53] that involved meta-analysis of genome-wide
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Table 4.5: List of gene sets from Molecular Signature Database identified
with additional adjustment with alcohol usage and socioeconomic status
with FDR ≤ 0.25.
Number
of
findings
Gene sets FDR
Gene ontology (GO) based gene sets
1. Thrombin activated receptor activity 0.07
2. G protein coupled receptor activity 0.08
3. Olfactory receptor activity 0.14
4. Protein domain specific binding 0.22
Curated gene sets
5. Aryl hydrocarbon receptor signalling 0.004
6. SHI SPARC targets up 0.16
Hallmark gene sets
7. UV response down 0.08
DNA methylation measured on 15907 blood-derived DNA samples from
participants in 16 cohorts. An integrative analysis of genome-wide DNA
methylation and transcriptomics data on the same participants is essential
for understanding smoking induced alterations in DNA methylation and its
consequences on the transcriptome. An integrative analysis could be done
at gene level by associating methylation levels in different genomic regions
of a gene and the transcriptomic profile of the same gene. Gene set analysis
can improve the power of such a study by analyzing the associations at
biological pathway level. For example, separate gene set analyses for CpGs
mapping to separate genomic regions such as coding or promoter regions
can provide a list of pathways that are hypo- or hypermethylated in specific
genomic regions of genes related to a pathway among smokers. Similarly,
gene set analysis of transcriptomic data of the same participants can provide
a list of pathways up or down regulated among smokers. Analyzing the
methylation pattern (hypo- or hypermethylation) in a pathway and the
direction of differential expression of the same pathway can provide insights
into epigenetic mechanisms by which smoking affects biological pathways.
Chapter 5
Summary and conclusions
The present study was performed to develop an efficient p-value estima-
tion method for permutation based GSA and an advanced permutation
method for sample permutation based GSA of complex experimental data
with more than two sample groups but less than six replicates per group.
Further, the GSA method developed in study I was used to identify smok-
ing related epigenetic signatures in the YFS cohort.
The main achievements of this study are:
I. Publication I addressed the problem of p-value estimation with sam-
ple permutation. The published method requires considerably fewer
permutations (~500) to accurately estimate p-values and thus speeds
up the gene set analysis process. In addition, this study presents
novel and robust ways to evaluate GSA methods.
II. Publication II addressed the problem of sample permutation in multi-
group data with fewer than six replicates. The study introduced
an advanced permutation method designed for data in question and
presented an improved evaluation method based on data splitting.
III. Publication III covered the application of the gene set analysis method
introduced in publication I to identify alterations in genome-wide
methylation patterns due to active smoking at the biological pathway
level. The flagship finding of the study is that the highly regenerating
olfactory sensing system responds to tobacco smoke and toxin expo-
sure through epigenetic mechanisms.
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Overall, the GSA approach holds great potential in the analysis of high-
throughput biological datasets as it captures the complex nature of biology
where molecules work together. This thesis contributed an improvement of
permutation based GSA methods and also introduced an exemplary imple-
mentation of a state-of-the-art GSA method for the analysis of genome-wide
methylation data with novel discoveries. Nonetheless, several limitations
still exist in GSA which need to be addressed.
Chapter 6
Future perspectives
The popularity and success of GSA in bioscience research across several
omics platform have motivated the development of more robust methods
as well as improvement of existing methods over [114, 34, 75, 127, 96, 67].
The GSA method has led to numerous biological discoveries. For example,
GSA of colorectal cancer datasets and glioblastoma multiforme datasets by
Drier et al. led to the identification of several gene sets significantly associ-
ated with survival of glioblastoma patients and two gene sets with predictive
ability for survival time in colorectal cancer [31]. Lee et al. identified muta-
tions responsible for metastatic breast cancers with a GSA based approach
[63]. Recently, Shen et al. used a GSA approach to develop immune-based
prognostic signatures to predict survival time in ovarian cancer patients
[107]. Similarly, with GSA, Gaspar et al. identified several drug classes
associated with major depressive disorder with drug repurposing potential
[37]. Thus, the implications of GSA range from quick and dirty hypothesis
generating exploratory analysis to the identification of molecular signatures
for diseases with predictive and prognostic value as well as drug discovery.
Study III of this thesis provided proof of concept that state-of-the-art sec-
ond generation gene set analysis methods are more powerful for the analy-
sis of epigenome-wide methylation data as compared to the predominantly
used overrepresentation based gene set analysis. HumanMethylation450
BeadChip has been replaced by Illumina, Inc. with the HumanMethyla-
tionEPIC BeadChip (EPIC), which is based on the same technology but
has increased genome coverage measuring methylation at >850,000 CpG
sites. GSA of methylation data generated with the improved array is more
reliable and reproducible which is crucial in understanding epigenetic mech-
anisms in health and disease [93].
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Next generation sequencing (NGS) technologies allow sequencing of the
complete set of miRNAs as well as mRNAs present in an RNA sample.
With the NGS driven increase in the amount of miRNAomics data, there
is growing demand of statistical methods including GSA methods. GSA
based integrative analysis of such data can be used to study interactome
and affected pathways of a disease that could potentially point out candi-
date markers for miRNA-based therapies [27]. GSA of miRNAomics has
several limitations at present, such as; i) most of such studies are based on
ORA [66, 27], ii) analysis is done indirectly with target mRNAs which could
lead to inaccurate results [40], and iii) FCS based GSA methods developed
for miRNAomics are based on gene permutation based GSEA which can
potentially lead to a high false positive rate [7]. Thus, there is clear need
for improvements in GSA methods as well as miRNA categories tailored
for miRNAomics data analysis.
The identification of molecular biomarkers that can help in prediction, di-
agnosis, or treatment of disease is an active field of research in genomic
medicine. The conventional method of identifyimg biomarkers from bulk
omics data from pooled cell populations can only provide answers at a gen-
eral level and misses cell specific information. Single-cell RNA sequencing
(scRNA-seq) technologies allow the study of gene expression at single-cell
resolution revealing the cellular heterogeneity of complex biological systems
underlying a disease. This allows the identification of marker genes specific
to organs [38]. However, rapid development of this field faces data analysis
related challenges as scRNA-seq data are noisier and complex as compared
to bulk RNA-seq data [19]. While more FCS based robust GSA methods
tailored for scRNA-seq data are needed [74], the methods will help to elu-
cidate several crucial questions such as biological process activities across
different cell types [29].
There are several other annotation as well as methodological limitations
of GSA [57]. The current knowledge bases for gene sets are based on low-
resolution information limited to whether or not a gene is active in a biolog-
ical pathway. Information at transcripts and single nucleotide variants level
generated by large numbers of RNA-seq and genome-wide association anal-
yses are missing in the current knowledge bases. One of the major issues
with current GSA is the lack of benchmark datasets for comparing different
methods. While development of new methods or improvement of existing
methods is important, the presence of several methods in the literature
creates confusion among end users in choosing one for their particular data
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and interest. Furthermore, as the performance of a method can be data
and interest specific, there is no standard way to compare or evaluate GSA
methods. This problem has been addressed by several workarounds such as
evaluating the methods with: i) artificial data [127, 128], ii) real biological
data using a priori knowledge from literature [114], iii) real biological data
on the same experiment done at multiple research centers [114, 128], and
iv) concordance test between the results from test and training sets from
a real biological data [34]. This thesis proposes that multiple evaluation
tests should be used by developers for evaluation and that the overall result
should be considered as the basis for ranking of methods. This approach
minimizes end-users’ confusion by presenting evaluation results from differ-
ent perspectives/methods.
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